Biosimilarity between Humira® and the Biosimilar Candidate SB5 in Product Quality

被引：0
|
作者：
Lee, Nayoung [1 ]
Kim, Minlee [1 ]
Lee, JongAh Joanne [1 ]
Kim, Soohwan [1 ]
Yang, Hahymn [1 ]
机构：
[1] Samsung Bioepis, Incheon, South Korea
来源：
ARTHRITIS & RHEUMATOLOGY | 2017年 / 69卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2495
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Consistency of Product Quality for SB5, an Adalimumab Biosimilar
    JongAh Joanne Lee
    Nayoung Lee
    Young Jun Seo
    Ilkoo Kim
    BioDrugs, 2023, 37 : 271 - 277
  • [2] Consistency of Product Quality for SB5, an Adalimumab Biosimilar
    Lee, JongAh Joanne
    Lee, Nayoung
    Seo, Young Jun
    Kim, Ilkoo
    BIODRUGS, 2023, 37 (02) : 271 - 277
  • [3] Demonstration of functional similarity of a biosimilar adalimumab SB5 to Humira®
    Lee, JongAh Joanne
    Yang, Junmo
    Lee, Changsoo
    Moon, Youngjin
    Ahn, Sehee
    Yang, Jiyoon
    BIOLOGICALS, 2019, 58 : 7 - 15
  • [4] SB5: An Adalimumab Biosimilar
    James E. Frampton
    BioDrugs, 2018, 32 : 507 - 510
  • [5] SB5: An Adalimumab Biosimilar
    Frampton, James E.
    BIODRUGS, 2018, 32 (05) : 507 - 510
  • [6] A PHASE I PHARMACOKINETIC STUDY COMPARING SB5, AN ADALIMUMAB BIOSIMILAR, AND ADALIMUMAB REFERENCE PRODUCT (HUMIRA®) IN HEALTHY SUBJECTS
    Shin, D.
    Kim, Y.
    Kim, H. S.
    Fuhr, R.
    Kornicke, T.
    ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 : 459 - 460
  • [7] Effectiveness and Safety of Adalimumab Biosimilar SB5 in Inflammatory Bowel Disease: Outcomes in Originator to SB5 Switch, Double Biosimilar Switch and Bio-Naive SB5 Observational Cohorts
    Derikx, Lauranne A. A. P.
    Dolby, Heather W.
    Plevris, Nikolas
    Lucaciu, Laura
    Rees, Caitlin S.
    Lyons, Mathew
    Siakavellas, Spyros, I
    Constantine-Cooke, Nathan
    Jenkinson, Philip
    Su, Shanna
    O'Hare, Claire
    Kirckpatrick, Laura
    Merchant, Lynne M.
    Noble, Colin
    Arnott, Ian D.
    Jones, Gareth-Rhys
    Lees, Charlie W.
    JOURNAL OF CROHNS & COLITIS, 2021, 15 (12): : 2011 - 2021
  • [8] SB5 adalimumab biosimilar in the treatment of psoriasis and psoriatic arthritis
    Di Cesare, Antonella
    Tronconi, Greta
    Fastame, Thais M.
    Rosi, Elia
    Pescitelli, Leonardo
    Ricceri, Federica
    Prignano, Francesca
    DERMATOLOGIC THERAPY, 2020, 33 (03)
  • [9] Sustained Efficacy and Comparable Safety and Immunogenicity after Transition to SB5 (an Adalimumab Biosimilar) Vs. Continuation of SB5 or Reference Adalimumab (Humira®) in Patients with Rheumatoid Arthritis: Results of Phase III Study
    Weinblatt, Michael
    Baranauskaite, Asta
    Niebrzydowski, Jaroslaw
    Dokoupilova, Eva
    Zielinska, Agnieszka
    Sitek-Ziolkowska, Karina
    Jaworski, Janusz
    Racewicz, Artur
    Pileckyte, Margarita
    Jedrychowicz-Rosiak, Krystyna
    Zhdan, Vyacheslav
    Cheong, Soo Yeon
    Ghil, Jeehoon
    ARTHRITIS & RHEUMATOLOGY, 2016, 68
  • [10] Efficacy after Transition to SB5 from Reference Adalimumab (Humira®) Vs. Continuation of SB5 or Reference Adalimumab By Antibodies Developed after Transition from a SB5 Phase III Study
    Genovese, Mark C.
    Weinblatt, Michael
    Keystone, Edward C.
    Baranauskaite, Asta
    Cheong, Soo Yeon
    Ghil, Jeehoon
    ARTHRITIS & RHEUMATOLOGY, 2016, 68
12345